Liquidia Corporation I Reports –

MORRISVILLE, NC, June 24, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (LQDA) today announced the grant of incentive stock options exercisable for a total of 24,800 common shares of Liquidia to newly hired non-executive employees under Liquidia Corporation 2022 Incentive Plan (the “Incentive scheme”). Each stock option was granted as an incentive for the beneficiary to accept employment with Liquidia (or one of its subsidiaries) as part of the beneficiary in accordance with Nasdaq listing rule 5635(c)(4).

The incentive plan is used exclusively for the granting of non-statutory stock option grants to persons who were not previously employees of Liquidia (or after a period of good faith non- Employment), as a material inducement to such person’s entry into employment with Liquidia, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

Each stock option is exercisable at a price of $5.79 per share, being the closing price of Liquidia common stock on May 20, 2022, the date of grant. Each stock option has a maximum term of ten years and vests over four years, with 25% of the award vesting on the first anniversary of the grant date, and an additional 1/48th of the award vesting monthly thereafter, subject to continuous service. until the applicable vesting dates (subject to the terms and conditions of the stock option agreement covering the award). Each stock option is subject to the terms and conditions of the Incentive Plan.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The Company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH markets pharmaceutical products against rare diseases, such as generic injectable treprostinil. For more information, please visit

Contact information

Media & Investors:
Jason Adair
Senior Vice President, Corporate Development and Strategy
[email protected]


Comments are closed.